Indenoisoquinoline LMP400 for Advanced Solid Tumors and Lymphomas
Status:
Completed
Trial end date:
2017-10-27
Target enrollment:
Participant gender:
Summary
Background:
- Indenoisoquinoline LMP400 is an experimental cancer treatment drug. It damages DNA in tumor
cells. Tumor cells with damaged DNA may die, resulting in cell death. Researchers want to see
if this drug is a safe and effective treatment for solid tumors and lymphomas that have not
responded to earlier treatment.
Objectives:
- To see if Indenoisoquinoline LMP400 is a safe and effective treatment for advanced solid
tumors or lymphomas.
Eligibility:
- Individuals at least 18 years of age who have solid tumors or lymphomas that have not
responded to treatment.
Design:
- Participants will be screened with a physical exam and medical history. Blood and urine
samples will be collected. Tumor samples may also be collected. The size and location of
the tumors will be determined with imaging studies.
- Indenoisoquinoline LMP400 is given in a 28-day cycle. Participants will receive the drug
by intravenous infusion on days 1, 8, and 15 of each cycle, followed by a break of 13
days without the drug.
- Treatment will be monitored with frequent blood tests and imaging studies. Tumor samples
will be optional.
- Participants will continue their cycles of treatment as long as the cancer does not grow
and there are no severe side effects.